Clinical Trials

Title   A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin versus Active Comparator in Pediatric Subjects with Acute Bacterial Skin and Skin Structure Infections
Description   To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.
IRB Number   17-073
Treatment   Pediatric Skin Infection
Status   Active
Principal Name   Haidee Custodio,, MD
Contact Name   hcustodio@health.southalabama.edu

Email Newsletters

Connect With Us